Vericel Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vericel Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $613 of operating cash. Higher than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$613Over the last 3 years, every $100 of reported profit came with $613 of operating cash.
Higher than 97% of Healthcare companies in United States.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Higher than 69% of Healthcare companies in United States.
Cash Locked Ratio
$31For every $100 of sales, $31 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $28 tied up three years earlier.
More money tied up than 68% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$30Sales grew 68% in 3 years; of every extra $100 of sales, $30 became extra profit.
Higher than 56% of Healthcare companies in United States.
Asset Productivity Ratio
+68% / +79%In 3 years sales changed by +68% while total assets changed by +79%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
3.7×Debt due within a year is covered 3.7 times by its yearly operating cash.
Higher than 78% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 64% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 88% of Healthcare companies in United States.
Tangible Net Worth Ratio
98%Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 89% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Vericel Corporation owes $0.26 for every $1 it owns. Net profit rose 59% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
91.4Investors pay $91.4 for every $1 of Vericel Corporation's yearly profit, higher than 89% of Healthcare companies in United States.
P/B ratio
5.95The share price is 5.95 times Vericel Corporation's book value per share, higher than 76% of Healthcare companies in United States.
Market cap
$2.2 BThe total market value of all of Vericel Corporation's shares at today's price (share price × number of shares), larger than 76% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$370 MWhat Vericel Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.23Net worth divided by the number of shares. The share price of $42.97 is 5.9 times this, which is the P/B above.
Return on equity (ROE)
7.2%Vericel Corporation earned 7.2% on its shareholders' money over the last year, higher than 81% of Healthcare companies in United States.
Owes vs Owns
0.26×Vericel Corporation owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
NoneVericel Corporation does not currently pay a dividend.
Revenue growth
+16%Revenue rose 16% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Profit growth
+59%Net profit rose 59% in the year to Dec 2025.
Profit margin
6.0%Vericel Corporation keeps $6 of every $100 of revenue as net profit.
Cash quality
3.1×Cash from Vericel Corporation's business was 3.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
17.5×Vericel Corporation's operating profit covered its interest costs 17.5 times in the year to Dec 2025.
Cash vs debt
Net cashVericel Corporation held $41 M more cash than debt (net cash) at Dec 2025.
Questions
What is Vericel Corporation's P/E ratio?
Investors pay $91.4 for every $1 of Vericel Corporation's yearly profit, higher than 89% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Vericel Corporation: $2.2 B ÷ $370 M (30 Jun 2026) = 5.9.
What is Vericel Corporation's return on equity?
Vericel Corporation earned 7.2% on its shareholders' money over the last year, higher than 81% of Healthcare companies in United States.
How much does Vericel Corporation owe compared with what it owns?
Vericel Corporation owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does Vericel Corporation pay a dividend?
No. Vericel Corporation does not currently pay a dividend.
Is Vericel Corporation's revenue growing?
Revenue rose 16% in the year to Dec 2025, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.